An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes

References

• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
   PubMed Web of Science ®Google Scholar
• Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56(4):686–695.
   PubMed Web of Science ®Google Scholar
• Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–794.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opin Pharmacother. 2017;18(5):503–515.
   PubMed Web of Science ®Google Scholar
• Holman RR, Steemson J, Turner RC, et al. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med. 1987;4(5):457–462.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A, et al. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7):1535–1540.
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Khunti K, Marx N, et al. First-line treatment for type 2 diabetes: is it too early to abandon metformin? Lancet. 2020;396(10264):1705–1707.
   PubMed Web of Science ®Google Scholar
• Colagiuri S, Matthews D, Leiter LA, et al. The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 2018;143:1–14.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Lee J, Choi S, et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3(1):43–51.
   PubMed Web of Science ®Google Scholar
• Maloney A, Rosenstock J, Fonseca V, et al. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019;105(5):1213–1223.
   PubMed Web of Science ®Google Scholar
• Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358(9294):1709–1716.
   PubMed Web of Science ®Google Scholar
• Hedrington MS, Davis SN. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2019;20(18):2229–2235.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.
   PubMed Web of Science ®Google Scholar
• Gale EAM. Troglitazone: the lesson that nobody learned? Diabetologia. 2006;49:1–6.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD, et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189–1195.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Guidance for industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, December 2008. Accessed 2021 May 1. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
   Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14): 1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with Ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435.
   PubMed Web of Science ®Google Scholar
• Arnott C, Li Q, Kang A, et al. Sodium-Glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(3):e014908.
   PubMed Web of Science ®Google Scholar
• Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237–1250.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–1529.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and Sodium-Glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–2031.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S111–S124.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–228.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461–2498.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;41:255–323.
   Web of Science ®Google Scholar
• Takeda Pharmaceuticals America Inc. Oseni (alogliptin and pioglitazone), prescribing information. 2013. Accessed 2021 Jul 1. https://general.takedapharm.com/OSENIPI
   Google Scholar
• Lee B, Shi L, Kassel DB, et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol. 2008;589(1–3):306–314.
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50:2297–2300.
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA, Schmidt WE, et al. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept. 2002;107(1–3):1–13.
   PubMedGoogle Scholar
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.
   PubMed Web of Science ®Google Scholar
• Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56(8):1951–1959.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705.
   PubMed Web of Science ®Google Scholar
• Gillies PS, Dunn CJ. Pioglitazone. Drugs. 2000;60(2):333–343. discussion 344-335.
   PubMed Web of Science ®Google Scholar
• Waugh J, Keating GM, Plosker GL, et al. Pioglitazone. Drugs. 2006;66(1):85–109.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167–174.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87(6):2784–2791.
   PubMed Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care. 2000;23(11):1605–1611.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab. 2008;10:1204–1211.
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547–1554.
   PubMed Web of Science ®Google Scholar
• Chiquette E, Ramirez G, Defronzo R, et al. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164(19):2097–2104.
   PubMedGoogle Scholar
• Defronzo RA, Tripathy D, Schwenke DC, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013;62(11):3920–3926.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292:E871–883.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D, Abdul-Ghani M, et al. The disposition index does not reflect beta-cell function in IGT subjects treated with pioglitazone. J Clin Endocrinol Metab. 2014;99:3774–3781.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–1184.
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–2307.
   PubMed Web of Science ®Google Scholar
• Della Pepa G, Russo M, Vitale M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract. 2021;178:108984.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Matsuda M, DeFronzo RA, et al. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(3):517–523.
   PubMed Web of Science ®Google Scholar
• Triplitt C, Cersosimo E, DeFronzo RA, et al. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag. 2010;6:671–690.
   PubMedGoogle Scholar
• Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513–527.
   PubMed Web of Science ®Google Scholar
• Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499–512.
   PubMed Web of Science ®Google Scholar
• Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(01):46–58.
   PubMedGoogle Scholar
• Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes. 2000;108(Sup. 2):234–242.
   Google Scholar
• Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl. 2001;121:19–25.
   PubMedGoogle Scholar
• Wittayalertpanya S, Chompootaweep S, Thaworn N, et al. The pharmacokinetics of pioglitazone in Thai healthy subjects. J Med Assoc Thai. 2006;89:2116–2122.
   PubMedGoogle Scholar
• Jaakkola T, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005;77(5):404–414.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet. 2007;46(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kadam R, Bourne D, Kompella U, et al. Effect of cytochrome P450 2C8*3 on the population pharmacokinetics of pioglitazone in healthy caucasian volunteers. Biol Pharm Bull. 2013;36(2):245–251.
   PubMed Web of Science ®Google Scholar
• Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49(10):1210–1219.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Incresync (alogliptin/pioglitazone): EU summary of product characteristics. 2014. Accessed 2021 Jul 1. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002178/WC500152197.pdf
   Google Scholar
• Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA 1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145–1152.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11:167–176.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63:46–55.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Fleck PR, Wilson CA, Alogliptin Study G., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–2317.
   PubMed Web of Science ®Google Scholar
• Cai Y, Zeng T, Wen Z, et al. Ethnic differences in efficacy and safety of alogliptin: a systematic review and meta-analysis. Diabetes Ther. 2018;9(1):177–191.
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696–708.
   PubMed Web of Science ®Google Scholar
• Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36(6):1789–1796.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• White WB, Heller SR, Cannon CP, et al. Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE trial. Am J Med. 2018;131(7):813–819 e815.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493): 1279–1289.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol. 2007;49(17):1772–1780.
   PubMed Web of Science ®Google Scholar
• Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone clinical trial in macroVascular events 04). Stroke. 2007;38:865–873.
   PubMed Web of Science ®Google Scholar
• Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572–2581.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10): 1180–1188.
   PubMed Web of Science ®Google Scholar
• de Jong M, van der Worp HB, van der Graaf Y, et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16:134.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14): 1321–1331.
   PubMed Web of Science ®Google Scholar
• Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887–897.
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339(dec03 1):b4731.
   PubMedGoogle Scholar
• Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(12):4605–4612.
   PubMed Web of Science ®Google Scholar
• Yang J, Vallarino C, Bron M, et al. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. Curr Med Res Opin. 2014;30(11):2223–2231.
   PubMed Web of Science ®Google Scholar
• Strongman H, Korhonen P, Williams R, et al. Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. 2017;5(1):e000364.
   PubMed Web of Science ®Google Scholar
• Strongman H, Christopher S, Majak M, et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care. 2018;6(1):e000481.
   PubMed Web of Science ®Google Scholar
• Morgan CL, Inzucchi SE, Puelles J, et al. Impact of treatment with pioglitazone on stroke outcomes: a real-world database analysis. Diabetes Obes Metab. 2018;20(9):2140–2147.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Reusch JE, Fleck PR, Alogliptin Study G., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25:2361–2371.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11): 2406–2408.
   PubMed Web of Science ®Google Scholar
• Bosi E, Ellis GC, Wilson CA, et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12): 1088–1096.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5): 1615–1622.
   PubMed Web of Science ®Google Scholar
• Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11): 1028–1035.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Rosenstock J, Seufert J, et al. Effect of combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes on β-cell function and insulin resistance. Diabetes. 2009;58:A520. Abstr 2026.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14(4):505–524.
   PubMed Web of Science ®Google Scholar
• White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(7):668–673.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E, et al. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–697.
   PubMed Web of Science ®Google Scholar
• Ryder RE. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabet Med. 2013;30(10):1148–1155.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals America Inc. Nesina (alogliptin), prescribing information. 2013. Accessed 2021 Jul 1. https://www.accessdata.fda.gov/drugsatfdadocs/label/2013/022271s000lbl.pdf
   Google Scholar
• Nagel AK, Ahmed-Sarwar N, Werner PM, et al. Dipeptidyl peptidase-4 inhibitor-associated pancreatic carcinoma: a review of the FAERS database. Ann Pharmacother. 2016;50:27–31.
   PubMed Web of Science ®Google Scholar
• Kaku K, Kisanuki K, Shibata M, et al. Benefit-risk assessment of alogliptin for the treatment of type 2 diabetes mellitus. Drug Saf. 2019;42(11):1311–1327.
   PubMed Web of Science ®Google Scholar
• Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29(3):510–514.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Chang AR, Henry RR, et al. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003;9:406–416.
   PubMedGoogle Scholar
• Zhang H, Zhang A, Kohan DE, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A. 2005;102:9406–9411.
   PubMed Web of Science ®Google Scholar
• Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11:861–866.
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003 Oct 7. 2003;108(23):2941–2948.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Inzucchi S, Abdul-Ghani M, et al. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133–143.
   PubMed Web of Science ®Google Scholar
• Horio T, Suzuki M, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens. 2005;18(7):949–957.
   PubMed Web of Science ®Google Scholar
• Clarke GD, Solis-Herrera C, Molina-Wilkins M, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care. 2017;40(11):1530–1536.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Harding S, Lam H, et al. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab. 2016;18(3):266–273.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265–277.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916–922.
   PubMed Web of Science ®Google Scholar
• Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(3):493–504.
   PubMed Web of Science ®Google Scholar
• Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ. 2016;354:i3903.
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet Med. 2011;28(7):759–771.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Kraenzlin ME, et al. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf. 2009;32(7):539–547.
   PubMed Web of Science ®Google Scholar
• Bazelier MT, De Vries F, Vestergaard P, et al. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne). 2013;4:11.
   PubMedGoogle Scholar
• Lin HF, Liao KF, Chang CM, et al. Use of thiazolidinediones and risk of hip fracture in old people in a case-control study in Taiwan. Medicine (Baltimore). 2017;96:e7712.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency. Pharmaceuticals and medical devices agency approved labels: liovel® label. Accessed 2021 Jul 1. Avalaible from https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400256_3969103F1024_1_16
   Google Scholar
• Blevins T. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin. Expert Opin Drug Saf. 2015;14(5):789–793.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Chilton R, Norton L, et al. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. Diabetes Obes Metab. 2016;18(5):454–462.
   PubMed Web of Science ®Google Scholar
• Ito D, Shimizu S, Inoue K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364–1372.
   PubMed Web of Science ®Google Scholar
• Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(7):1617–1635.
   PubMed Web of Science ®Google Scholar
• Fitipaldi H, McCarthy MI, Florez JC, et al. A global overview of precision medicine in type 2 diabetes. Diabetes. 2018;67(10):1911–1922.
   PubMed Web of Science ®Google Scholar
• Dennis JM, Henley WE, Weedon MN, et al. Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care. 2018;41(9):1844–1853.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–2948.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR, et al. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Vijayakumar TM, Jayram J, Meghana Cheekireddy V, et al. Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review. Curr Ther Res Clin Exp. 2017;84:4–9.
   PubMed Web of Science ®Google Scholar
• Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2020;11(4):1020–1076.
   PubMed Web of Science ®Google Scholar
• Lautsch D, Alsumali A, McLeod E, et al. Comparative efficacy of dual and single initiation of add-on oral antihyperglycemic agents in type 2 diabetes uncontrolled on metformin alone: a systematic literature review and network meta-analysis. Diabetes Ther. 2021;12(1):389–418.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2015. Accessed 2021 Jul 1. Available from https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493
   Google Scholar